Pharmacologic activation of stress-responsive signaling pathways provides a promising approach for ameliorating imbalances in proteostasis associated with diverse diseases. However, this approach has not been employed in vivo. Here we show, using a mouse model of myocardial ischemia/reperfusion, that selective pharmacologic activation of the ATF6 arm of the unfolded protein response (UPR) during reperfusion, a typical clinical intervention point after myocardial infarction, transcriptionally reprograms proteostasis, ameliorates damage and preserves heart function. These effects were lost upon cardiac myocyte-specific Atf6 deletion in the heart, demonstrating the critical role played by ATF6 in mediating pharmacologically activated proteostasis-based protection of the heart. Pharmacological activation of ATF6 is also protective in renal and cerebral ischemia/reperfusion models, demonstrating its widespread utility. Thus, pharmacologic activation of ATF6 represents a proteostasis-based therapeutic strategy for ameliorating ischemia/reperfusion damage, underscoring its unique translational potential for treating a wide range of pathologies caused by imbalanced proteostasis.
Protein homeostasis, or proteostasis is maintained by pathways that coordinate protein synthesis and folding with the degradation of misfolded, potentially toxic proteins1,2. Endoplasmic reticulum (ER) proteostasis is particularly important, since nearly one-third of all proteins are made and folded in the ER, then transported to their final destinations as integral membrane or soluble secreted proteins3. Imbalances in proteostasis cause or exacerbate numerous pathologies, spawning interest in the exogenous manipulation of proteostasis as a therapeutic approach for such diseases4. ER proteostasis is regulated by the unfolded protein response (UPR), a stress-responsive signaling pathway comprising three sensors/effectors of ER protein misfolding; PERK (protein kinase R [PKR]-like ER kinase), IRE1 (inositol-requiring enzyme 1), and ATF6 (activating transcription factor 6)5. Considerable evidence supports ATF6, a transcriptional regulator of ER proteostasis, as a viable therapeutic target for exogenous manipulation of proteostasis6,7,8,9,10,11; however, such an approach has not been examined in vivo. Accordingly, here, we determined whether treatment with a pharmacological activator of ATF6 would reprogram proteostasis and mitigate pathology in a mouse model of ischemic diseases, such as those that affect the heart.
Ischemic heart disease is the leading cause of human deaths worldwide12. These deaths are mainly due to acute myocardial infarction (AMI), where thrombotic coronary artery occlusion causes rapid, irreparable ischemic injury to the heart, increasing susceptibility to progressive cardiac degeneration and eventual heart failure13,14,15. The treatment of choice for AMI is primary percutaneous coronary intervention, or coronary angioplasty16, which results in reperfusion. While reperfusion limits ischemic injury, the reperfusion itself injures the heart, in part by increasing reactive oxygen species (ROS). ROS contribute to AMI injury, also known as ischemia/reperfusion (I/R) injury, mainly by damaging proteins, which impairs proteostasis17,18. In fact, reperfusion accounts for up to 50% of the final damage from AMI19; however, there is no clinically available intervention that mitigates reperfusion injury at the time of coronary angioplasty, underscoring the importance of developing therapies that reduce ROS during reperfusion19. Using a mouse model of global Atf6 deletion, we recently showed that, in the heart, ATF6 is responsible for the expression of a broad spectrum of genes not traditionally identified as regulated by ATF6, including many antioxidant genes that could improve proteostasis during I/R10. While this genetic approach identified the potential importance of ATF6 as a novel therapeutic target for pharmacological intervention in I/R injury models, there have been no reports addressing whether a single arm of the UPR can be pharmacologically activated and shown to be beneficial in any animal model of pathology.
We recently identified a compound that we call 147 in a high-throughput cell-based reporter screen, where it was shown to selectively induce only the ATF6 arm of the UPR20. Here, we examined the effects of pharmacological activation of ATF6 with 147 in a mouse model of AMI. We found that intravenous administration of 147 concurrently with AMI robustly and selectively activated ATF6 and downstream genes of the ATF6 gene program and protected the heart from I/R damage; however, this protection was lost upon the genetic deletion of Atf6. Moreover, 147 had no deleterious effects in the absence of pathology, or in other tissues that were unaffected by I/R, an indicator of its safety. Remarkably, we found that by activating ATF6, 147 protected other tissues, including the brain, kidney, and liver, when they were subjected to maneuvers that induced I/R damage and impaired proteostasis. Thus, 147 selectively activates the ATF6 arm of the UPR in vivo, exhibiting significant potential as a therapeutic approach for treating I/R damage in a wide range of tissues.
ATF6 in cardiac myocytes protects the heart from I/R injury
Given their roles in contraction, the viability of cardiac myocytes is crucial for heart function, and cardiac myocyte death during I/R leads to impairment of this function17. Accordingly, we examined the effects of I/R on proteostasis in isolated cardiac myocytes and in the mouse heart, positing that I/R disrupts proteostasis, leading to activation of all three arms of the UPR, and that the ATF6 arm induces genes that adaptively reprogram proteostasis, decrease myocyte death, and provide cardioprotection from I/R damage (Fig. 1a). Consistent with this hypothesis was our finding that I/R activated ATF6, as well as the IRE1 and PERK arms of the UPR in cultured cardiac myocytes, albeit to a lesser extent than the chemical activator of the UPR, tunicamycin (TM) (Supplementary Figure 1a–d). As a measure of ATF6 activation, we examined the expression of two known ATF6 target genes, glucose-regulated protein 78 kDa (Grp78), a well-studied ER heat-shock protein 70 chaperone, also known as BiP21, which participates in ER protein folding, and catalase (Cat), a prominent member of a novel antioxidant gene program recently shown to be induced by ATF610. In accordance with the increased activity of ATF6 in response to I/R, both Grp78 and Cat were induced in cultured cardiac myocytes (Supplementary Figure 1a, e, f, g).
To examine the effects of deleting Atf6 specifically from cardiac myocytes, in vivo, we made an Atf6 conditional knockout (ATF6 cKO) mouse in which Atf6 was selectively deleted in cardiac myocytes of ATF6fl/fl mice using adeno-associated virus serotype 9 (AAV9)-cTnT-CRE (Supplementary Figure 2a, b). ATF6 cKO and wild-type (WT) mice, the latter of which retain Atf6, were subjected to 30 min of surgical coronary artery ligation, followed by 24 hours of reperfusion (I/R), which mimics the reperfusion injury in AMI patients that occurs acutely, a time during which the extent of reperfusion injury is progressive22. In this model, I/R causes cardiac myocyte death and irreparable damage in the infarct zone (Fig. 1b, black), where blood flow has been completely occluded. However, cardiac myocytes adjacent to the infarct, in the border zone (Fig. 1b, red), are exposed to sub-lethal I/R and mount protective stress responses, such as the UPR, while the remote region (Fig. 1b, blue) is relatively unaffected13,23. Thus, protective stress responses in border zone myocytes conserve their viability, thereby reducing the size of the infarct. WT mice exhibited a robust activation of ATF6 in response to I/R, as evidenced by induction of the ATF6 target genes, Grp78 and Cat, in the border zone of hearts subjected to acute I/R (Fig. 1c, e); however, this induction was lost in ATF6 cKO mice (Fig. 1d, f). In contrast, the IRE1 target gene, Erdj4, and PERK target gene, Atf4, were similarly induced by I/R in WT and ATF6 cKO mouse hearts (Supplementary Figure 2c, d). However, compared to WT, ATF6 cKO mice had increased infarct sizes and plasma cardiac troponin I (cTnI) (Fig. 1g, h), canonical indicators of cardiac injury, and exhibited increased lipid peroxidation (Supplementary Figure 2e), a measure of ROS-mediated damage. Cardiac hemodynamics were also assessed in an ex vivo isolated perfused heart model that enables the precise measurement of the strength of cardiac pump function, that is, left ventricular developed pressure (LVDP), with each contraction in response to I/R injury10. ATF6 cKO mouse hearts exhibited significantly lower recovery of LVDP and larger infarcts than WT hearts (Fig. 1i, j). Collectively, these results show that ATF6 in cardiac myocytes protects the heart from I/R injury. Thus, while all three arms of the UPR were activated in the ischemic mouse heart, cardiac specific deletion of Atf6 significantly increased heart damage in response to I/R, demonstrating the importance of the ATF6 arm of the UPR in mitigating I/R injury in the heart.
In the days following AMI, the infarct continues to expand and remodels to become a fibrotic scar, so the detrimental effects of I/R on cardiac function and performance are often more pronounced a week after infarction13. Therefore, to examine the effect of Atf6 deletion on cardiac function and performance, mice were analyzed 7 days after AMI. ATF6 cKO mice exhibited significantly reduced fractional shortening compared to WT, despite being aphenotypic at baseline (Fig. 2a; Supplementary Table 1). ATF6 cKO mice also exhibited exaggerated pathological cardiac hypertrophy and increased plasma cTnI (Fig. 2b, c). Notably, the levels of Grp78 and Cat were lower in ATF6 cKO than WT mice at 7 days (Fig. 2d, e). When gene expression was examined at 1 and 7 days after AMI, the induction of Atf6 and its target genes remained increased through 7 days in WT and less so in ATF6 cKO mouse hearts, although the level of induction was lower at 7 days compared to 1 day post AMI (Fig. 2f), indicating that the adaptive effects of ATF6-induced genes are likely exerted for at least the first week following AMI. Grp78 and Cat were also increased in hearts from patients with ischemic heart disease (Fig. 2g), supporting the relevance of the ATF6 adaptive arm of the UPR in human pathology and validating the phenotypes observed in this mouse model of AMI.
Interestingly, I/R activated ATF6 less than TM, the latter of which is a strong, chemical inducer of ER protein misfolding and activator of the UPR (Supplementary Figure 1a). Importantly, this result suggests that during I/R there is a reserve of inactive ATF6 that has the potential to be activated. Accordingly, we hypothesized that selective pharmacologic activation of ATF6 could supplement the modest ATF6 activation achieved upon I/R, and that this supplemental ATF6 activation might enhance cardioprotection.
147 activates ATF6 and its target genes in cardiac myocytes
The compound 147 was previously shown to specifically activate ATF6 in HEK293 cells through a mechanism involving translocation of ATF6 from the ER to the Golgi, where it is cleaved by S1 and S2 proteases to release the active ATF6 transcription factor20 (Fig. 3a). The translocation of ATF6 out of the ER during protein misfolding is known to require a reduction of the inter- and intramolecular disulfide bonds in ATF6; however, neither the effects of 147 on ATF6 nor its mechanism of action have been studied in cardiac myocytes. Here, in cultured neonatal rat ventricular myocytes (NRVM), a control compound that closely resembles 147 (Fig. 3b), but does not activate ATF6, did not affect the disulfide bond status of ATF6, while 147 reduced intramolecular disulfide bonds in ATF6 (Fig. 3c, lanes 7–10). Moreover, while the control compound did not activate any of the UPR pathways, 147 activated ATF6, but not PERK or IRE1 (Supplementary Figure 3a-d). Thus, in cardiac myocytes, 147 induced the reduction of disulfide bonds in ATF6, which is associated with ATF6 translocation to the Golgi. Coordinate with the generation of the active, nuclear form of ATF6 in the Golgi was our finding that 147 increased the nuclear translocation of ATF6 in cardiac myocytes (Fig. 3d) and increased the specific cleavage and activation of ATF6 (Supplementary Figure 3a, b, g). Mechanistically, 147 increased the association of ATF6 with known ATF6 binding sites in the Grp78 and Cat promoters (Fig. 3e), and 147 increased GRP78 and CAT (Supplementary Figure 3a, e, f). Intravenous administration of 147 activated ATF6 and increased Grp78 and Cat expression in WT mouse hearts; however, this effect was completely absent in ATF6 cKO mice (Fig. 3g–j; Supplementary Figure 3h). As a testament to the ability of 147 to activate only the ATF6 arm of the UPR was our finding that 147 had no effect on the expression levels of the IRE1 or PERK targets, Erdj4 or Atf4 in either WT or ATF6 cKO mouse hearts (Supplementary Figure 3i, j). Thus, 147 selectively activates the ATF6 arm of the UPR in the heart, in vivo, as it does in cultured cardiac myocytes.
147 improves ER proteostasis and decreases oxidative stress
Mechanistically, we examined whether 147 could replicate the breadth of adaptive effects of ATF6 on ER proteostasis, such as increasing ER-associated protein degradation (ERAD), which removes potentially toxic terminally misfolded proteins, increasing folding and subsequent secretion of proteins made in the ER, and enhancing protection against ER protein misfolding. 147 increased ERAD, as measured by the rate of degradation of ectopically expressed T cell antigen receptor α-chain (TCRα)24 (Fig. 4a, b), increased the folding and secretion of protein from the ER pathway (Fig. 4c), and protected cells from death in response to ER protein misfolding induced by TM (Fig. 4d); importantly, all of these effects were lost upon knockdown of Atf6. Next, we explored whether 147 could replicate the adaptive effects of ATF6 against oxidative stress, in vitro. 147 significantly improved the survival of cardiac myocytes subjected to I/R (Fig. 4e) and decreased ROS-mediated damage (Fig. 4f). Importantly, these effects of 147 were lost upon siRNA-mediated knockdown of Atf6. Thus, 147 replicated a broad spectrum of the adaptive effects of ATF6 on proteostasis and oxidative stress. Moreover, all of these effects required endogenous ATF6, demonstrating the ATF6-dependent mechanism of action of 147.
147 in vivo protects cardiac myocytes and hearts in vitro
To determine whether 147 can protect cardiac myocytes in vivo, mice were treated for 24 hours with either the negative control compound or 147, after which cardiac myocytes were isolated and subjected to I/R in culture. Compared to the negative control, myocytes from 147-treated WT mice exhibited increased viability when subjected to I/R in vitro (Fig. 4g, left); however, this benefit was absent in myocytes from ATF6 cKO mice (Fig. 4g, right). Thus, when administered in vivo, 147 protected cardiac myocytes from I/R damage in culture, and this protection was mediated through endogenous ATF6. To determine whether the protection seen in isolated cardiac myocytes had any effect in the intact heart, hearts from WT and ATF6 cKO mice that had been treated for 24 hours with 147 were examined in the ex vivo I/R model. Compared to control, hearts from 147-treated WT mice had greater LVDP recovery and smaller infarct sizes (Fig. 4h, blue vs. red; 4i, left). Notably, 147 exhibited neither of these beneficial effects in hearts from ATF6 cKO mice (Fig. 4h, gray and black; 4i, right). Thus, when administered to mice, 147 protected cardiac myocytes, and decreased I/R injury of the heart while preserving cardiac function. Furthermore, all of these beneficial effects of 147 were dependent upon endogenous ATF6 in cardiac myocytes.
147 transiently activates ATF6 in the heart
To begin to understand the temporal dynamics of the function of 147 in mice, a time course of gene induction was performed. Atf6 and its target genes were induced at the earliest time point examined, 8 hours, reaching a maximum 24 hours after administration and falling back to baseline values by 7 days after administration (Fig. 5a). Furthermore, pharmacokinetic studies revealed a relatively rapid clearance of 147 from plasma (Fig. 5b), supporting the further examination of multiple 147 dosing strategies. Accordingly, several dosing strategies spanning 7 days were used to examine the temporal dynamics of the effects of 147 on ATF6 target gene induction in the hearts of mice that were not subjected to I/R using several dosing protocols spanning 7 days (Fig. 6a). Mice were injected with the negative control compound or 147 either twice, at days 0 and 4 (Experiments 1 and 2, respectively), or 147 was injected only once, at day 0 (Experiment 3). Compared to Experiment 1, Experiment 2 but not 3 resulted in the increased expression of the ATF6-regulated genes Grp78 and Cat (Fig. 6b, c, e), but not the IRE1-regulated Erdj4 or the PERK-regulated Atf4 (Supplementary Figure 4a, b). These results indicated that 147-mediated induction of ATF6 target genes is transient, as gene expression was increased 3 days after administration, but returned back to baseline 7 days after administration.
Interestingly, Experiment 2 significantly enhanced cardiac performance (Fig. 5d; Experiment 1 vs. 2; Supplementary Table 2), which could be partly due to 147-dependent increases in Atp2a2 expression (Supplementary Figure 4c). Atp2a2 encodes SERCA2a, an adaptive SR/ER-localized calcium ATPase previously shown to be ATF6-inducible in the heart25 and to improve contractility in heart failure patients26. None of the 147 dosing protocols resulted in pathological remodeling of the heart (Supplementary Figure 4d; Supplementary Table 2), cardiotoxicity, as evidenced by no increased plasma cTnI (Supplementary Figure 4e) or cardiac pathology-associated genes, such as Nppa, Nppb, Col1a1, or Myh7 (Supplementary Figure 4f). Furthermore, no apparent deficits were observed in any of the experiments upon inspection of the liver or kidneys when steatosis and glomerular filtration rate were assessed by hepatic triglyceride accumulation and creatinine clearance, respectively (Supplementary Figure 4g, h). These results indicate a time course of gene induction and no toxic side effects of 147 that support the efficacy of 147 when administered in the setting of an I/R injury, either as a single dose or as part of a serial dosing regimen.
147 protects the heart from I/R injury in vivo
Next, the effects of 147 were examined in an in vivo model of I/R damage in the heart 7 days after reperfusion (Fig. 7a). In Experiments 1 and 2, the negative control compound or 147, respectively, were administered 24 hours prior to AMI, with a second dose at reperfusion and a third dose 4 days later. In Experiment 3, 147 was administered at reperfusion and again 4 days later. In Experiment 4, 147 was administered only one time, at reperfusion. Given the transient nature of 147, we designed our multiple-dose strategy so that it mimics a therapeutic approach used for treating AMI patients as soon as possible after the infarction, to mitigate the initial reperfusion damage to the heart, as well as days later to ameliorate the detrimental effects of continued expansion of infarct damage and cardiac remodeling in the infarct and infarct border zones on heart pump function. Strikingly, cardiac performance was preserved to similar extents in all experiments involving 147 (Fig. 7b), as was the ability of 147 to reduce cardiac hypertrophy, which is a pathological response to I/R in this model (Fig. 7c). 147 decreased plasma cTnI in all of the experiments, though somewhat less so in Experiments 3 and 4 (Fig. 7d). Importantly, 147 preserved diastolic cardiac function and left ventricular volumes in all of the experiments (Fig. 7e–g; Supplementary Table 3), showing that 147 impeded the progression toward heart failure. In Experiments 2 and 3, the beneficial structural and functional effects were accompanied by increased expression of the ATF6-regulated genes, Grp78 and Cat (Fig. 7h–i; Supplementary Figure 5a), but not Erdj4 and Atf4 (Supplementary Figure 5b, c). However, in Experiment 4, the levels of Grp78 and Cat were comparable to control-treated animals, as expected, given the transient nature of 147-mediated gene induction seen in a previous experiment (see Fig. 6). Moreover, I/R induced cardiac pathology genes (Supplementary Figure 5d, Sham vs. Experiment 1), as expected; however, these effects were blunted by 147 (Supplementary Figure 5d, Experiments 2–4). In addition, decreased levels of pro-apoptotic cleaved caspase-3 were seen in Experiments 2–4 (Supplementary Figure 5e), indicating that 147 protected myocytes from apoptosis during I/R. Thus, pharmacologic ATF6 activation at reperfusion ameliorated pathologic cardiac dysfunction in response to I/R injury.
147 is beneficial in a wide range of disease models in vivo
Next, we examined the effects of 147 following 24 hours of administration, an important time at which AMI patients are often treated by coronary angioplasty. Additionally, since ATF6 is expressed in all cells, we posited that it might be effective in tissues in addition to the heart. Accordingly, in addition to the heart, we determined the effects of 147 in the liver, kidney, and brain. 147 activated ATF6 target genes in all four of the tissues, as evidenced by significant increases in of Grp78 and Cat (Fig. 8a, b), although the magnitude of the responses varied somewhat between tissues. The functionality of 147-mediated activation of ATF6 in the liver was evident in that it significantly reduced ER protein misfolding, measured by XBP1 splicing, in mice that had been injected with TM; this beneficial effect was lost upon genetic deletion of Atf6 (Fig. 8c). Additional evidence of the functionality of 147 in the liver was evident in its ability to reduce hepatic triglycerides, which are a hallmark of hepatic steatosis, demonstrating improved ER proteostasis in the liver (Fig. 8d, blue); this beneficial effect of 147 was also lost upon deletion of ATF6 (Fig. 8d, black).
Next, to examine the functional effects of 147 in the various tissues, the control compound or 147 were administered, as shown in Fig. 8e, and the effects were examined on tissue damage in the heart via the acute I/R model, the kidney via transient unilateral renal portal system occlusion, and in the brain via transient unilateral middle cerebral artery (MCA) occlusion. Throughout the studies, the surgeon and the data analyst were blinded to the animal assignments, which were predetermined by a separate investigator. Remarkably, even when administered only at the time of reperfusion, 147 significantly decreased infarct sizes in all three tissues when measured 24 hours after I/R (Fig. 8f–h; Supplementary Figure 6a). Moreover, 147 decreased plasma cTnI and creatinine, which are biomarkers of cardiac and kidney damage, respectively, and it improved behavioral indicators of post-ischemic neurological damage (Fig. 8i–k). As expected, since 24 hours after reperfusion is too short for structural remodeling, there were no observable deficits on cardiac performance, chamber size, or pathological hypertrophy, as monitored by echocardiography (Supplementary Table 4). As further proof of concept, this experiment was replicated in female mice and, again, both Experiments 2 and 3 conferred protection as evidenced by reduced infarct sizes and plasma cTnI (Supplementary Figure 6b, c). Importantly, these beneficial effects of 147 in response to myocardial acute I/R were not seen in ATF6 cKO mice, further emphasizing that 147-mediated protection of the heart required ATF6 activation (Supplementary Figure 6d, e). Interestingly, the beneficial effects of 147 were also seen in a different AMI model induced by acute administration of the β-adrenergic receptor agonist, isoproterenol, which is known to cause widespread oxidative damage and cardiac myocyte death in mice at this dose (Supplementary Figure 6f–h).
Thus, when administered at the time of injury, 147 protected a wide range of tissues from I/R damage, emphasizing the broad spectrum of potential applications for this compound as a transcriptional regulator of the ATF6 arm of the UPR and subsequent reprogramming of proteostasis, in vivo.
After an AMI, upon reconstituting blood flow, reperfusion damage begins almost immediately and continues for at least 3 days27. The initial reperfusion damage is thought to be due ROS generation by mitochondria in the myocardium, while the longer term damage may be due to multiple mechanisms, including continued ROS generation by the infiltration of inflammatory cells into the infarct zone13,28. Therefore, an effective therapy for AMI should function over a timeframe spanning at least 3 days. While a number of potential therapies that act acutely to minimize reperfusion damage have been tested, many of them have failed to move through the drug development process and there is still no clinically available intervention15. At the outset of the current study, we posited that this might be because most of the previous therapeutics function only during the initial stages of reperfusion, losing efficacy in the ensuing days. Furthermore, many of the initial trials performed in small animals have not tested therapies at times that accurately mimic typical clinical interventions (i.e., during coronary angioplasty) and have not adhered to the Food and Drug Administration's (FDA’s) Good Laboratory Practices. Accordingly, in addition to addressing these points in the design of our animal experiments here, we examined the therapeutic function after both 1 and 7 days of reperfusion. We also set out to develop a therapeutic approach that would exert beneficial effects through multiple mechanisms in various cellular locations, which we felt would broaden the potential utility to include different tissues and widen the scope to multiple proteostasis-based pathologies. In this regard, we focused on ATF6, since it adaptively reprograms ER proteostasis by inducing a wide range of protective response genes that encode proteins, such as catalase and grp78, which act to mitigate ROS-induced damage, as well as emending ROS-independent proteostasis pathways, respectively (Fig. 9). Using this strategy, we found that selective pharmacologic activation of only the ATF6 arm of the UPR with 147 in mice acted within 1 day to reduce reperfusion damage in the heart. Moreover, we found that 147 acted after 7 days to preserve cardiac function. This timing of these beneficial effects is consistent with the timing of adaptive ATF6 target gene induction and the reperfusion damage that takes place over this same time frame, although we cannot rule out an effect of 147 on reducing damage during ischemia. In addition to demonstrating its efficacy in the heart, we found that 147 protected the liver in a mouse model of dysregulated hepatic proteostasis, and it protected the kidneys and brain in models of renal and cerebral I/R damage. These findings, together with a recent report showing that 147 enhances the differentiation of human embryonic stem cells29, support the broad therapeutic potential of pharmacologic activation of ATF6 for treating a wide range of proteostasis-based pathologies in various tissues.
In terms of its suitability as a pharmacologic agent, 147 exhibits many desirable properties. For example, 147 is highly specific, serving as the first example of a compound that selectively activates only one arm of the UPR, ATF6, which is well known for exerting mainly beneficial effects in many different cell types. 147 is highly efficacious in vivo, functioning at a dose similar to many other cardiovascular drugs and has the capacity to cross the blood–brain barrier. Moreover, 147 does not exhibit any apparent toxicity or deleterious off-target effects in vivo. Both the efficacy and tolerance of 147 can be attributed in large part to the high-stringency, cell-based transcriptional profiling that was done in the initial screening to ensure that 147 specifically activates only the ATF6 arm of the UPR, instead of global UPR activation20. The relatively transient activation of ATF6 by 147 in vivo is also potentially advantageous, since many stress-signaling pathways, including the UPR, can be beneficial initially, but damaging upon chronic activation30. Since I/R only partially activates ATF6, the remaining inactive ATF6 provides a therapeutic reserve for 147 to activate, allowing it to boost adaptive ATF6 signaling pathways in multiple tissues, in vivo. Remarkably, we found that 147 exerted beneficial effects in the hearts of mice that were not subjected to any injury maneuvers, underscoring the safety, and perhaps even benefits of the compound in healthy tissues. Thus, while future pharmacokinetic and toxicology studies will address further details of 147 action, it is clear from the results presented here that 147 is easily administered, well tolerated, acts quickly, boosts an endogenous adaptive transcriptional stress-signaling pathway, and has no apparent off-target or untoward effects, all of which are attributes of an excellent candidate for therapeutic development.
Impaired proteostasis contributes to numerous pathologies and even impacts aging31. Thus, global improvement of proteome quality through pharmacologic activation of defined transcriptional regulators of proteostasis should ameliorate a broad range of proteostasis-based diseases. Recent findings showing that the sphere of influence of the UPR, in particular, the ATF6 arm of the UPR, extends well beyond the ER to reprogram proteostasis in many cellular locations10, support the potential broad spectrum of impact of pharmacologic compounds, like 147. The results presented here provide proof of principle that this type of pharmacologic correction can be achieved with well-characterized compounds, such as 147, that selectively activate a specific protective aspect of UPR signaling.
The research reported in this article complies with all relevant ethical regulations and has been reviewed and approved by the San Diego State University Institutional Animal Care and Use Committee (IACUC), and conforms to the Guide for the Care and Use of Laboratory Animals published by the National Research Council. ATF6-floxed mice were a generous gift from Gokhan S. Hotamisligil. Briefly, ATF6-floxed mice were generated with a targeting construct flanking exons 8 and 9 of ATF6 with LoxP sequences on a C57B/6J background, as previously described32. For preclinical efficacy testing of experimental compounds, WT 10-week-old male or female C57B/6J mice were used (The Jackson Laboratory, Bar Harbor, ME, USA). For some experiments, we determined the number of animals to use based on a predictive power analysis to achieve 5% error and 80% power, or using the resource equation method33. In other experiments, the number of animals to use were determined practically, based on previous experiments designed to determine, for example, surgery mortality rates and the approximate magnitude of changes in the measured parameters. This was the case in experiments using ATF6 cKO mice. Our previous experiments showed that the variation in infarct size between littermates post in vivo I/R surgeries was low, amounting to <5%10. All animal work was performed at the same time of the circadian rhythm typical of animals housed on a 12-h light–dark cycle with ad libitum feeding. All studies in which compound 147 was administered to mice were conducted such that the surgeon and data analyst were blinded to the group assignments. Prior to all experiments, animals were assigned codes by one investigator, while investigator #2 was blinded to animal codes and nature of the treatments, for example, control vs. compound 147, performed the surgeries and echocardiographic analysis. Investigator #3 analyzed the areas at risk and infarct regions for all cardiac, renal, and cerebral I/R injury models; as with investigator #2, this investigator was also blinded to the animal codes and treatments. Animals were not decoded until after all surgical, functional, and histological analyses were fully analyzed and relevant statistical assessments had been calculated for all parameters measured. For all animal experiments involving cKO of ATF6, ATF6-floxed littermates were randomly assigned to receive AAV-control or AAV-Cre (1:1 ratio) to minimize mouse-to-mouse variability. Animals involved in I/R experiments involving administration of either the control compound or compound 147, WT 10-week-old male or female C57B/6J littermates. Consistency and, therefore, minimal variability of infarct sizes following ex vivo and in vivo I/R studies was ensured through blinded measurements of areas at risk relative to total left ventricular areas, as described above. As a result, we observe a variation in area at risk/left ventricle area (AAR/LV) within experimental groups of <5%. For ex vivo I/R studies, mechanical error and variability were maintained as low as possible by minimizing the time between animal sacrifice and initiation of retroperfusion; our criteria is that this process must take <60 s. We found that this results in a relatively rapid progression to equilibration of heart function during ex vivo perfusion; our criteria for reaching equilibration of LVDP is <15 min after initiation or retroperfusion on the Langendorff apparatus.
Human heart explants were obtained from ventricular myocardium of patients with advanced ischemic heart failure. Control patient ventricular explants were obtained from non-failing donor hearts deemed unsuitable for transplantation for non-cardiac reasons. Samples were collected with informed consent and complying with all relevant ethical regulations as previously described34. All study procedures were approved by the University of Pennsylvania Hospital Institutional Review Board.
Adeno-associated virus serotype 9
The plasmid encoding the human cardiac troponin T promoter driving Cre-recombinase was provided as a gift from Dr. Oliver Muller35. AAV9 preparation and injection were carried out as previously described10,24. Non-anesthetized 8-week-old ATF6-floxed mice were injected with 100 μl of AAV9-control or AAV9-cTnT-Cre containing 1 × 1011 viral particles via the lateral tail vein using a 27-guage syringe and housed for 2 weeks before either sacrifice or experimental initiation.
Cardiomyocyte isolation, culture, and experimental design
Neonatal rat ventricular myocytes (NRVMs) were isolated via enzymatic digestion, purified by Percoll density gradient centrifugation, and maintained in Dulbecco’s modified Eagle’s medium (DMEM)/F12 supplemented with 10% fetal bovine serum (FBS) and antibiotics (100U/ml penicillin and 100 µg/ml streptomycin) on plastic culture plates that had been pre-treated with 5 µg/ml fibronectin, as previously described10,24. For all NRVM experiments, plating density was maintained at 4.5 × 105 cells per well on 12-well plates. Adult mouse ventricular myocytes (AMVMs) were isolated from WT or ATF6 cKO mice 24 h after intravenous (IV) injection of control compound (2 mg/kg) or compound 147 (2 mg/kg). AMVM isolation was performed by cannulating the ascending aorta, followed by retroperfusion and collagenase digestion, as previously described10. For all experiments, AMVMs were plated at a density of 5.0 × 105 cells per well on 24-well plates that had been pre-treated with laminin (10 µg/ml) and incubated in maintaining medium (MEM medium, 1× insulin-transferrin-selenium, 10 mM HEPES, 1.2 mM CaCl2, and 0.01% bovine serum albumin, 25 μM blebbistatin) for 16 h before initiating experiments as previously described10. Sixteen hours after plating, NRVMs and AMVMs were treated with control compound (10 µM), compound 147 (10 µM), or TM (10 µg/ml) for 24 h in DMEM/F12 supplemented with bovine serum albumin (BSA) (1 mg/ml) for NRVMs, or maintaining media for AMVMs. For in vitro I/R, ischemia was simulated by replacing all culture media with 0.5 ml of glucose-free DMEM containing 2% dialyzed FBS with either the control compound (10 µM) or compound 147 (10 µM), and then incubated at 0.1% O2 in a hypoxia chamber with an oxygen controller (ProO × P110 oxygen controller, Biospherix, Parish, NY, USA) for 8 or 3 h for NRVMs or AMVMs, respectively, as previously described10. Reperfusion was simulated by replacing culture media with DMEM/F12 supplemented with BSA (1 mg/ml) for NRVMs or maintaining media for AMVMs and incubating at 21% O2 for an additional 24 h. NRVM and AMVM reperfusion media were supplemented with control compound (10 µM) or compound 147 (10 µM) throughout the duration of the reperfusion period. Viability was determined as the number of calcein-AM-labeled NRVMs or rod-shaped calcein-AM-labeled AMVMs, using calcein-AM green (Thermo Fisher). Images were obtained with an IX70 fluorescence microscope (Olympus, Melville, NY, USA). The number of viable, calcein-AM green-positive cells were counted using ImageJ or Image-Pro Plus software (Medium Cybernetics, Rockville, MD, USA).
Transfection of small interfering RNA (siRNA) into NRVMs was achieved using HiPerfect Transfection Reagent (Qiagen, Valencia, CA, USA) following the vendor’s protocol. Briefly, NRVM culture medium was replaced with DMEM/F12 supplemented with 0.5% FBS without antibiotics, 120 nM siRNA, and 1.25 µl HiPerfect/1 µl siRNA, and then incubated for 16 h, after which the culture medium was replaced with DMEM/F12 supplemented with BSA (1 mg/ml) for an additional 48 h. The sequence of siRNA targeting rat ATF6 was 5-GCUCUCUUUGUUGUUGCUUAGUGGA-3, the sequence targeting rat catalase was 5-GGAACCCAAUAGGAGAUAAACUUAA-3 (cat# CatRSS302058, Stealth siRNA, Thermo Fisher), and the sequence targeting rat grp78 was 5-AGUGUUGGAAGAUUCUGA-3 (cat# 4390771, Stealth siRNA, Thermo Fisher) as previously described10. A non-targeting sequence (cat# 12935300, Thermo Fisher) was used as a control siRNA.
NRVMs were lysed and subjected to immunoblot analysis, as previously described10. In brief, cultures were lysed with VC lysis buffer made from 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100, protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA), and phosphatase inhibitor cocktail (Roche Diagnostics). Samples comprising 10 µg of protein were mixed with Laemmli sample buffer, boiled, then subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by transfer onto PVDF membranes for immunoblotting. Full-length Atf6 (p90) was detected with an antibody from SAB Signalway Antibody (1:1000, cat# 32008, College Park, MD, USA), while active Atf6 (p50) was detected with an antibody from Proteintech (1:1000, cat# 24169-1-AP, Rosemont, IL, USA). Other antibodies used include: anti-KDEL antibody (1:8000, cat# ADI-SPA-827, Enzo Life Sciences, Farmingdale, NY, USA), which was used to detect GRP78, anti-catalase (1:1000, cat# ab16731, Abcam), anti-IRE1 (1:500, cat# sc-390960, Santa Cruz), anti-XBP1s (1:1000, cat# 619502, BioLegend, San Diego, CA, USA), anti-phospho-PERK (1:1000, cat# 3179, Cell Signaling), anti-PERK (1:1000, cat# 3192, Cell Signaling), anti-Anp (1:4000, cat# T-4014, Peninsula), anti-Gapdh (1:25,000, cat# G109a, Fitzgerald Industries International Inc.), HA-probe F-7 (Santa Cruz, SC-7392; 1:1000), and anti-FLAG (1:3000, cat#F1804, Sigma-Aldrich, St. Louis, MO, USA). The oxidation state of ATF6 in NRVMs treated with 147 was analyzed by gel-shift essentially as previously described32. Briefly, cells were lysed in low-stringency lysis buffer comprising 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) and phosphatase inhibitor cocktail (Roche Diagnostics) and 20 µM 4-acetamido-4ʹ-maleimidylstilbene-2,2ʹ-disulfonic acid, disodium salt (AMS) (Thermo Fisher, cat# A485). AMS binds covalently to reduced thiols, typically on cysteine residues, and increases their molecular mass in SDS-PAGE. Thus, proteins that exhibit an upward shift when analyzed under non-reducing conditions compared to reducing are considered to have reduced thiols.
Quantitative reverse transcription PCR
Total RNA was extracted from left ventricular extract using the RNeasy Mini Kit (Qiagen) as previously described10. All qPCR probes were obtained from Integrated DNA Technologies and primer sequences are listed in Supplementary Table 5.
Immunocytochemistry and immunohistochemistry
NRVMs and AMVMs were plated on fibronectin- and laminin-coated glass chamber slides, respectively, as previously described10. In brief, cells were fixed with 4% paraformaldehyde, followed by permeabilization with 0.5% Triton X. Adult mouse hearts were paraffin-embedded after fixation in neutral-buffered 10% formalin via abdominal aorta retroperfusion as previously described10. The infarct border zone was imaged in hearts subjected to surgical I/R. The infarct border zone was identified as an area that stained positively for the cardiac muscle protein tropomyosin that was adjacent to an area that did not stain for tropomysin (infarct zone) due to the absence of viable myocytes. The left ventricular free wall was imaged in sham and non-injured hearts. Primary antibodies used were anti-α-actinin (1:200, cat# A7811, Sigma-Aldrich), anti-tropomyosin (1:200, cat# T9283, Sigma-Aldrich), anti-GRP78 (C-20, 1:30, cat# SC-1051, Santa Cruz), anti-catalase (1:100, Abcam), anti-ATF6 (targeting to N terminus of ATF6, 1:50, cat# sc-14250, Santa Cruz), and anti-cleaved caspase-3 (1:100, cat# D175, Cell Signaling). Slides were incubated with appropriate fluorophore-conjugated secondary antibodies (1:100, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) followed by nuclei counter-stain Topro-3 (1:2000, Thermo Fisher). Images were obtained using laser scanning confocal microscopy on an LSM 710 confocal laser scanning microscope (Carl Zeiss, Oberkochen, Germany).
ERAD was determined using a C-terminal HA-tagged version of the model chronic misfolded substrate, TCR-α-HA, as previously described24.
Luciferase secretion assay
Secretory capacity of cardiac myocytes was determined essentially as described36. Briefly, NRVMs were co-transfected with pcDNA plasmid as well as p-SV-β-galactosidase control vector and pCMV-GLuc plasmid (NEB, N8081S) using FuGENE6 (2 µg complementary DNA (cDNA), 2:1, FuGENE:cDNA).
Chromatin immunoprecipitation (ChIP) assays were performed essentially as previously described10. Briefly, AdV-FLAG-ATF6(1–670)-infected NRVMs were treated with fixing buffer (50 mM HEPES-KOH, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, and 1% formaldehyde) for 10 min, quenched with 125 mM glycine, and scraped into ice-cold phosphate-buffered saline (PBS). Cells were centrifuged, resuspended in lysis buffer (50 mM HEPES, pH 7.9, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100, and protease inhibitor cocktail), and incubated on ice for 10 min. After centrifugation at 1800 × g for 10 min, the pellets were washed with buffer containing 10 mM Tris, pH 8.1, 200 mM NaCl, 1 mM EDTA, and 0.5 mM EGTA, resuspended in shearing buffer (0.1% SDS, 1 mM EDTA, and 10 mM Tris, pH 8.1), and then transferred to microTUBEs (Covaris, Woburn, MA, USA). Chromatin was sheared by sonication for 15 min using an M220 focused ultrasonicator (Covaris). Triton X-100 and NaCl were added to the final concentration of 1% Triton and 150 mM NaCl followed by centrifugation at 16,000 × g for 10 min. Immunoprecipitation was performed by incubated 140 μl of sheared chromatin with 5 μg of anti-FLAG antibody (cat# F1804, Sigma-Aldrich) and 260 μl of immunoprecipitation buffer (0.1% SDS, 1 mM EDTA, 10 mM Tris, pH 8.1, 1% Triton X-100, and 150 mM NaCl) at 4 °C overnight. Protein A/G magnetic beads (5 μl, BcMag, Bioclone, San Diego, CA, USA) were added to the mixtures and incubated at 4 °C for 1.5 h. Magnetic beads were sequentially washed with low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM HEPES-KOH, pH 7.9, and 150 mM NaCl), high salt wash buffer with 500 mM NaCl, LiCl wash buffer (100 mM Tris-HCl, pH 7.5, 0.5 M LiCl, 1% NP-40, and 1% deoxycholate acid), and TE buffer (10 mM Tris-HCl, pH 8.0, and 0.1 mM EDTA). Immune complexes were eluted by incubating beads with proteinase K digestion buffer (20 mM HEPES, pH 7.9, 1 mM EDTA, 0.5% SDS, and 0.4 mg/ml proteinase K) at 50 °C for 15 min. Formaldehyde cross-linking was reversed by incubating with 0.3 M NaCl and 0.3 mg/ml RNase A at 65 °C overnight. Samples were further incubated with 550 μg/ml proteinase K at 50 °C for 1 h. DNA was purified using NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel, Bethlehem, PA, USA) and eluted by 30 μl of water. Two microliters of DNA was used for qRT-PCR analysis with primers targeting rat Hspa5 (5ʹ-GGTGGCATGAACCAACCAG-3ʹ and 5ʹ-GCTTATATATCCTCCCCGC-3), rat Cat ERSE-1 (5ʹ-CTACCCACCAATTAGTACCAAATAA-3ʹ and 5ʹ-AGAAGGGACAGGATTGGAAG-3ʹ), rat Cat ERSE-2 (5ʹ-CACATTCTAGGGACAGTGTAGATG-3ʹ and 5ʹ-ACCTTGATTATGGGCTGTGG-3ʹ), rat Pdia6 ERSE (5ʹ-CACATGAGCGAAATCCACAGA-3ʹ and 5ʹ-ACTAGTCGAGCCATGCTGAT-3ʹ), rat HO-1 (5ʹ-GGGCTACTCCCGTCTTCCTG-3ʹ and 5ʹ-CCTTTCCAGAACCCTCTACTCTACTC-3ʹ), or rat Gapdh (5ʹ-ATGCGGTTTCTAGGTTCACG-3ʹ and 5ʹ-ATGTTTTCTGGGGTGCAAAG-3ʹ). Pdia6 served as a positive control for a known ATF6 target gene in cardiac myocytes, while HO-1 and Gapdh served as negative controls as previously described37. ChIP signals obtained from the qRT-PCR were normalized to the input DNA.
Ex vivo I/R
Hearts from WT or ATF6 cKO mice that had previously received 2 mg/kg IV administration of control compound or compound 147 were rapidly excised and cannulated via the ascending aorta and subjected to global I/R, as previously described38. Here, the hearts were subjected to 20 min global no-flow ischemia followed by reperfusion for 1 h. LVDP was measured using a pressure sensor balloon placed into the left ventricle and analyzed using the Powerlab software (ADInstruments, Colorado Springs, CO, USA).
In vivo myocardial I/R
Surgical myocardial I/R was performed as previously described10. Briefly, mice were anesthetized with 2% isoflurane and a thoracotomy was performed to isolate the heart, after which the left anterior descending coronary artery (LAD) was ligated with a 6-0 Prolene suture for 30 min, followed by suture removal and either 24 h or 7 days of reperfusion. Regional ischemia was confirmed by visual inspection of the discoloration of the myocardium distal of the ligation, which is characteristic of impaired blood flow. Animals assigned as shams underwent the thoracotomy surgical procedure, but were not subjected to LAD ligation. Animals were randomly assigned to experimental groups prior to outset of the experiment by a single investigator, while the surgeon and data analyst were blinded to group assignments. Animals designated to receive either control compound or compound 147 at the time of reperfusion received 2 mg/kg of respective compounds via IV injection 5 min prior to release of the ligation. Twenty-four hours after reperfusion, 1% of Evans Blue was injected apically to determine the AAR. Hearts were harvested and 1-mm sections of the hearts were stained with 1% 2,3,5-triphenyltetrazolium chloride (TTC) to measure the infarcted area (INF) as previously described36. The AAR, INF, and LV from digitized images of heart sections were analyzed using the ImageJ software. For all infarct data presented, respective AAR was normalized to total LV area and all compared experiments displayed the same AAR/LV ratios. A separate investigator analyzed the AAR, INF, and LV and was blinded to the animal assignments. Just prior to sacrifice, post I/R, animals were anesthetized and 0.5 ml of arterial blood were obtained via inferior vena cava puncture as previously described33. Blood was placed in heparin- and EDTA-coated vacutainer (BD Vacutainer) and centrifuged at 1800 × g for 10 min and plasma samples were analyzed for cTnI with a Mouse cTnI High-Sensitivity ELISA Kit (Life Diagnostics Inc.).
In vivo renal I/R
Surgical renal I/R was performed as previously described39. Briefly, mice were anesthetized with 2% isoflurane and a 3 cm incision was made upon the abdominal midline and the abdominal cavity entered via an incision along the linea alba. The right kidney was visualized and separated from surrounding connective tissue. The right ureter and right renal portal system was permanently ligated and a right unilateral nephrectomy performed. Subsequently, the left kidney was visualized and separated from surrounding connective tissue. A Bulldog Clamp (Fine Science Tools, Foster City, CA, USA) was applied temporarily ligating the left renal portal system for a period of 30 min. Global ischemia was confirmed by visual inspection of the discoloration of the kidney of the ligation, which is characteristic of impaired blood flow. After that duration, the Bulldog Clamp was removed and the abdomen closed with instant tissue adhesive. Animals were randomly assigned to experimental groups prior to outset of the experiment by a single investigator, while the data analyst was blinded to experiment assignments. Animals designated to receive either control compound or compound 147 at the time of reperfusion received 2 mg/kg of respective compounds via IV injection 5 min prior to release of the ligation. Twenty-four hours after reperfusion, kidneys were harvested and 1-mm sections of the kidneys were stained with 1% TTC to measure the INF as previously described39. Just prior to sacrifice, post I/R, animals were anesthetized and 0.5 ml of arterial blood were obtained via inferior vena cava puncture as previously described40. Blood was placed in heparin- and EDTA-coated vacutainer (BD Vacutainer) and centrifuged at 1800 × g for 10 min and plasma samples were analyzed for creatinine as a measure of glomerular filtration rate and renal functional output with a Creatinine Assay Kit (Abcam).
In vivo cerebral I/R
Surgical cerebral I/R was performed as previously described11. Briefly, mice were anesthetized with 2% isoflurane and a 3 cm incision was made along the midline of the ventral surface of the neck along the left side of the trachea. The left external and internal carotid arteries were visualized and dissected from surrounding connective tissue without disturbing tangential nerves. An 8-0 catheter filament 10 mm in length (Doccol Corporation) was to be inserted into the MCA via the internal carotid artery. This occluded blood flow to the MCA and was left in position for a period of 30 min. After that duration, the catheter was removed and the neck closed with instant tissue adhesive. Animals were randomly assigned to experimental groups prior to outset of the experiment by a single investigator, while the data analyst was blinded to experimental assignments. Animals designated to receive either control compound or compound 147 at the time of reperfusion received 2 mg/kg of respective compounds via IV injection 5 min prior to release of the ligation. Twenty-four hours after reperfusion, brains were harvested and 1-mm sections of the brains were stained with 1% TTC to measure the INF as previously described41. Just prior to sacrifice, animals were assigned a behavioral score to assess the severity of neurological function and deficit as a result of the cerebral ischemia. The scoring was performed based on the Bederson Neurological Examination Grading System42, where a grade of 0 corresponded to a normal function with no observable deficit, grade 1 to a moderate deficit with animals exhibiting forearm flexion, grade 2 to a severe deficit with decreased resistance to a lateral push when suspended by the tail and lethargy, and grade 3 to a severe deficit with extreme lethargy and circling behavior in the cage.
Hepatic triglyceride assay
Hepatic triglyceride assay was performed as previously described43. Briefly, livers were harvested and 10 mg extracts were homogenized and analyzed for triglyceride content using the EnzyChrom Triglyceride Assay Kit (BioAssay Systems).
Transthoracic echocardiography was performed using an ultrasound imaging system (Vevo 2100 System, Fujifilm VisualSonics, Toronto, ON, Canada) as described24. Diastolic function was determined as previously described40. Briefly, echocardiography coupled with pulse-wave Doppler was used to visualize transmitral flow velocities and were recorded by imaging the mitral orifice at the point of the mitral leaflets. Waveforms were recorded and analyzed for peak early- and late-diastolic transmitral flow velocities corresponding to E and A waves, respectively.
Acute isoproterenol myocardial damage
Myocardial damage was induced by administering high-dose (200 mg/kg) isoproterenol via intraperitoneal injection in mice as previously described40.
Lipid peroxidation was determined by measuring the levels of malondialdehyde using a TBARS Assay Kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions as previously described10.
In vivo experimental compound administration
Control compound and compound 147 were suspended to a final concentration of 0.2 mg/ml in 10% dimethyl sulfoxide. Mice were weighed prior to administration of compounds and, subsequently, non-anesthetized 10-week-old WT or ATF6 cKO mice were injected with ~250 µl of stock compounds via the lateral tail vein depending upon body mass to ensure accurate administration of 2 mg/kg. This dose was established in preliminary experiments with the control compound or compound 147 where it was shown to activate Atf6 in vivo; the prototypical UPR inducer, TM, which was also administered to mice at 2 mg/kg, as previously shown44 was used as a control. Since compound 147 and TM have similar molecular weights, this dose of 147 is near the molar equivalent of the typical dose of TM. It is relevant to note that for compound 147, a dose of 2 mg/kg is similar to FDA-approved cardiovascular drugs, such as many angiotensin-converting enzyme inhibitors, which are used in small animal models at 2 mg/kg45.
For studies involving induction of myocardial damage, either through surgical I/R or isoproterenol administration, cohort sizes were based on a predictive power analysis to achieve 5% error and 80% power. All acute in vivo I/R studies in which compound 147 were conducted such that the surgeon and data analyst was blinded to the group assignments. Two-group comparisons were performed using Student’s two-tailed t test, and all multiple group comparisons were performed using a one-way analysis of variance (ANOVA) with a Newman–Keuls post hoc analysis. Data are represented as mean with all error bars indicating ± s.e.m. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request and a reporting summary is available as a supplementary file.
Hartl, F. U., Bracher, A. & Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature 475, 324–332 (2011).
Labbadia, J. & Morimoto, R. I. The biology of proteostasis in aging and disease. Annu. Rev. Biochem. 84, 435–464 (2015).
Das, I. et al. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 348, 239–242 (2015).
Roth, D. M. & Balch, W. E. Modeling general proteostasis: proteome balance in health and disease. Curr. Opin. Cell Biol. 23, 126–134 (2011).
Walter, P. & Ron, D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 334, 1081–1086 (2011).
Smith, M. H., Ploegh, H. L. & Weissman, J. S. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. Science 334, 1086–1090 (2011).
Chiang, W. C., Hiramatsu, N., Messah, C., Kroeger, H. & Lin, J. H. Selective activation of ATF6 and PERK endoplasmic reticulum stress signaling pathways prevent mutant rhodopsin accumulation. Invest. Ophthalmol. Vis. Sci. 53, 7159–7166 (2012).
Cooley, C. B. et al. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc. Natl. Acad. Sci. USA 111, 13046–13051 (2014).
Martindale, J. J. et al. Endoplasmic reticulum stress gene induction and protection from ischemia/reperfusion injury in the hearts of transgenic mice with a tamoxifen-regulated form of ATF6. Circ. Res. 98, 1186–1193 (2006).
Jin, J. K. et al. ATF6 decreases myocardial ischemia/reperfusion damage and links ER stress and oxidative stress signaling pathways in the heart. Circ. Res. 120, 862–875 (2017).
Yu, Z. et al. Activation of the ATF6 branch of the unfolded protein response in neurons improves stroke outzcome. J. Cereb. Blood Flow Metab. 37, 1069–1079 (2017).
Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017).
Frangogiannis, N. G. Pathophysiology of myocardial infarction. Compr. Physiol. 5, 1841–1875 (2015).
Hausenloy, D. J. & Yellon, D. M. The evolving story of “conditioning” to protect against acute myocardial ischaemia–reperfusion injury. Heart 93, 649–651 (2007).
Bulluck, H., Yellon, D. M. & Hausenloy, D. J. Reducing myocardial infarct size: challenges and future opportunities. Heart 102, 341–348 (2016).
Hausenloy, D. J. & Yellon, D. M. Ischaemic conditioning and reperfusion injury. Nat. Rev. Cardiol. 13, 193–209 (2016).
Kalogeris, T., Baines, C. P., Krenz, M. & Korthuis, R. J. Ischemia/reperfusion. Compr. Physiol. 7, 113–170 (2016).
Murphy, E. & Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemia–reperfusion injury. Physiol. Rev. 88, 581–609 (2008).
Yellon, D. M. & Hausenloy, D. J. Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121–1135 (2007).
Plate, L. et al. Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation. Elife 5, https://doi.org/10.7554/eLife.15550 (2016).
Wang, J., Lee, J., Liem, D. & Ping, P. HSPA5 gene encoding Hsp70 chaperone BiP in the endoplasmic reticulum. Gene 618, 14–23 (2017).
Kumar, M. et al. Animal models of myocardial infarction: mainstay in clinical translation. Regul. Toxicol. Pharmacol. 76, 221–230 (2016).
Dixon, J. A. & Spinale, F. G. Pathophysiology of myocardial injury and remodeling: implications for molecular imaging. J. Nucl. Med. 51, 102S–106S, https://doi.org/10.2967/jnumed.109.068213 (2010).
Doroudgar, S. et al. Hrd1 and ER-associated protein degradation, ERAD, are critical elements of the adaptive ER stress response in cardiac myocytes. Circ. Res. 117, 536–546 (2015).
Thuerauf, D. J. et al. Sarco/endoplasmic reticulum calcium ATPase-2 expression is regulated by ATF6 during the endoplasmic reticulum stress response: intracellular signaling of calcium stress in a cardiac myocyte model system. J. Biol. Chem. 276, 48309–48317 (2001).
Gwathmey, J. K., Yerevanian, A. & Hajjar, R. J. Targeting sarcoplasmic reticulum calcium ATPase by gene therapy. Hum. Gene Ther. 24, 937–947 (2013).
Baines, C. P. How and when do myocytes die during ischemia and reperfusion: the late phase. J. Cardiovasc. Pharmacol. Ther. 16, 239–243 (2011).
Hernandez-Resendiz, S. et al. The role of redox dysregulation in the inflammatory response to acute myocardial ischaemia–reperfusion injury–adding fuel to the fire. Curr. Med. Chem. 25, 1275–1293 (2018).
Kroeger, H. et al. Induction of endoplasmic reticulum stress genes, BiP and chop, in genetic and environmental models of retinal degeneration. Invest. Ophthalmol. Vis. Sci. 53, 7590–7599 (2012).
Ron, D. & Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell. Biol. 8, 519–529 (2007).
Martinez, G., Duran-Aniotz, C., Cabral-Miranda, F., Vivar, J. P. & Hetz, C. Endoplasmic reticulum proteostasis impairment in aging. Aging Cell 16, 615–623 (2017).
Engin, F. et al. Restoration of the unfolded protein response in pancreatic beta cells protects mice against type 1 diabetes. Sci. Transl. Med. 5, 211ra156 (2013).
Charan, J. & Kantharia, N. D. How to calculate sample size in animal studies? J. Pharmacol. Pharmacother. 4, 303–306 (2013).
Bedi, K. C. Jr. et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133, 706–716 (2016).
Werfel, S. et al. Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase. Cardiovasc. Res. 104, 15–23 (2014).
Lynch, J. M. et al. A thrombospondin-dependent pathway for a protective ER stress response. Cell 149, 1257–1268 (2012).
Vekich, J. A., Belmont, P. J., Thuerauf, D. J. & Glembotski, C. C. Protein disulfide isomerase-associated 6 is an ATF6-inducible ER stress response protein that protects cardiac myocytes from ischemia/reperfusion-mediated cell death. J. Mol. Cell. Cardiol. 53, 259–267 (2012).
Jin, J. K. et al. Localization of phosphorylated alphaB-crystallin to heart mitochondria during ischemia–reperfusion. Am. J. Physiol. Heart Circ. Physiol. 294, H337–344 (2008).
Wei, Q. & Dong, Z. Mouse model of ischemic acute kidney injury: technical notes and tricks. Am. J. Physiol. Ren. Physiol. 303, F1487–1494 (2012).
Wallner, M. et al. Acute catecholamine exposure causes reversible myocyte injury without cardiac regeneration. Circ. Res. 119, 865–879 (2016).
Xie, M. et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 129, 1139–1151 (2014).
Bederson, J. B. et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17, 472–476 (1986).
DeZwaan-McCabe, D. et al. ER stress inhibits liver fatty acid oxidation while unmitigated stress leads to anorexia-induced lipolysis and both liver and kidney steatosis. Cell Rep. 19, 1794–1806 (2017).
Wu, J. et al. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev. Cell 13, 351–364 (2007).
Eckman, E. A. et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J. Biol. Chem. 281, 30471–30478 (2006).
We thank Dr. Gokhan S. Hotamisligil (Harvard T.H. Chan School of Public Health, Boston, MA, USA) who generated and kindly provided the ATF6afl/fl mice, Dr. Randal Kaufman (Sanford Burham Prebys Medical Discovery Institute, La Jolla, CA, USA), who generated the global ATF6 KO mice, and Dr. Oliver Muller (University of Kiel, Arnold-Heller-Str.3, Kiel, Germany), for providing us with the cTNT-Cre plasmid that was used to prepare AAV9. Human heart tissue was obtained from Dr. Kenneth B. Margulies (Heart Failure and Transplantation, Translational Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA). This work was supported by grants from the National Institutes of Health to C.C.G. (R01 HL75573, R01 HL104535, and P01 HL085577), J.W.K. (R01 AG046495), R.L.W. (R01 DK102635, R01 DK107604, R01 NS092829, UL1TR001114), a fellowship to Lars Plate from the Leukemia and Lymphoma Society, and grants and fellowships to E.A.B. from the American Heart Association (17PRE33670796), Rees-Stealy Research Foundation and SDSU Heart Institute, the Inamori Foundation, and the ARCS Foundation Inc., San Diego Chapter.
The authors declare no competing interests.
Journal peer review information: Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Blackwood, E.A., Azizi, K., Thuerauf, D.J. et al. Pharmacologic ATF6 activation confers global protection in widespread disease models by reprograming cellular proteostasis. Nat Commun 10, 187 (2019). https://doi.org/10.1038/s41467-018-08129-2
This article is cited by
Andrographolide-treated bone marrow mesenchymal stem cells-derived conditioned medium protects cardiomyocytes from injury by metabolic remodeling
Molecular Biology Reports (2023)
Pharmacological activation of ATF6 remodels the proteostasis network to rescue pathogenic GABAA receptors
Cell & Bioscience (2022)
Cell Death & Disease (2022)
Nature Reviews Drug Discovery (2022)
Nature Communications (2022)